MediciNovaMNOV +0.53%33 Days Payable is 396.40 as of Mar. 2026, which is 52% below its 10-year median of 831.60. GuruFocus rates MNOV with a GF Score™ of 33/100. The stock has 2 warning signs investors should review. Among 707 Biotechnology companies, MediciNova ranks better than 78.08% on this metric.
MediciNova's average Accounts Payable for the
three
months ended in Mar. 2026 was $0.74 Mil. MediciNova's Cost of Goods Sold for the
three
months ended in Mar. 2026 was $0.17 Mil.
Hence, MediciNova's Days Payable for the
three
months ended in Mar. 2026 was 396.40.
The historical rank and industry rank for MediciNova's Days Payable or its related term are showing as below:
MNOV'
s Days Payable Range Over the Past 10 Years
Min: 466.85 Med: 831.6 Max: 831.6
Current: 466.85
During the past 13 years, MediciNova's highest Days Payable was 831.60. The lowest was 466.85. And the median was 831.60.
MNOV's Days Payable is ranked better than 78.08% of 707
companies
in the Biotechnology industry
Industry Median: 113.76
vs MNOV: 466.85
MediciNova's Days Payable
increased
from Mar. 2025 (0.00) to Mar. 2026 (396.40).
It may suggest that MediciNovadelayed paying its suppliers.
MediciNova Days Payable Related Terms
MediciNova Days Payable Historical Data
* Premium members only.
The historical data trend for MediciNova's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, MediciNova's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MediciNova Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MediciNova's Days Payable distribution charts can be found below:
* The bar in red indicates where MediciNova's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
MediciNova's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MediciNova (MNOV) has a Days Payable of 396.40 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on MediciNova and its competitors. This is 52% below median its historical median of 831.60. Over the past decade, MediciNova's Days Payable has ranged from 466.85 to 831.60. According to the industry distribution chart, MediciNova ranks #155 out of 707 companies in the Biotechnology industry, placing it in the top 21.9%.
Is MediciNova's Days Payable too high?
MediciNova's current Days Payable of 396.40 is 52% below median its 10-year median of 831.60. Over the past 10 years, this metric has ranged from a low of 466.85 to a high of 831.60. The Biotechnology industry median Days Payable is 113.76. MediciNova's value of 396.40 is 248.5% above this industry median. Based on the distribution chart, MediciNova ranks #155 out of 707 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, MediciNova has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does MediciNova's Days Payable compare to ENTX and IMA?
According to the Biotechnology industry distribution chart, MediciNova ranks #155 out of 707 companies for Days Payable. This places MediciNova in the top 22% of its industry — outperforming the majority of peers. The industry median Days Payable is 113.76. MediciNova's value of 396.40 is 248.5% above this benchmark. Historically, MediciNova's own Days Payable has ranged from 466.85 to 831.60 over the past decade. While the company's 10-year median is 831.60 vs. the industry median of 113.76, MediciNova has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.76, based on 707 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MediciNova's current Days Payable of 396.40 is 248.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on MediciNova and its competitors. For the Biotechnology industry, the median Days Payable is 113.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MediciNova's current Days Payable is 396.40, which is 52% below median its own 10-year median of 831.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MediciNova stock overvalued right now?
MediciNova (MNOV) has a current Days Payable of 396.40. The current Days Payable is 396.40, which is 52% below median its 10-year median of 831.60 and 248.5% above the Biotechnology industry median of 113.76. MediciNova's overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For MediciNova (MNOV), the current Days Payable is 396.40 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.
33GF Score
Get the complete analysis for MNOV
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MNOV has been successfully added to your 
